Piper Sandler last night downgraded Kronos Bio (KRON) to Neutral from Overweight with a price target of $1, down from $6. The company is discontinuing development of istisociclib due to adverse events in five of seven ovarian cancer patients and exploring strategic alternatives, the analyst tells investors in a research note. The firm believes the company will implement cost-cutting initiatives to preserve cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRON:
- Kronos Bio downgraded to Neutral from Overweight at Piper Sandler
- Kronos Bio reports Q3 EPS (23c), consensus (28c)
- Kronos Bio files $250M mixed securities shelf
- Kronos Bio to present data at ASH annual meeting on p300 KAT inhibitor program
- KRON Earnings Report this Week: Is It a Buy, Ahead of Earnings?